Evidence map›Paper›PMID 40680377›Full record

ArticleVaccine2025

Lyme disease vaccine acceptability among healthcare providers - United States, 2018 and 2022.

Taylor D Bostic, Sarah A Hook, Grace E Marx

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Taylor D BosticDivision of Vector-borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA; Oak Ridge Institute for Science and Education, Centers for Disease Control and Prevention Fellowship Program, Oak Ridge, TN, USA.
Sarah A HookDivision of Vector-borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA.
Grace E MarxDivision of Vector-borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA. Electronic address: GMarx@cdc.gov.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundA Lyme disease (LD) vaccine is expected to become available soon. We aimed to understand recent trends in healthcare provider (HCP) willingness to recommend LD vaccination.

methodsCross-sectional surveys among HCPs were conducted in 2018 and 2022. We compared willingness to recommend LD vaccination by survey year and provider characteristics.

resultsAmong 3005 HCPs, 70.5 % reported willingness to recommend LD vaccination. This proportion was lower in 2022 than in 2018 (68 % vs 73 %; p < 0.01) and did not differ significantly by provider medical specialty. More HCPs in states with high LD incidence were willing to recommend the vaccine compared to HCPs in neighboring or low-incidence states (p < 0.01). Vaccine safety was the most frequently reported consideration for recommending LD vaccination (73 %).

conclusionsHCP willingness to recommend LD vaccination decreased from 2018 to 2022. Vaccination education tailored to HCPs that address vaccine safety will be critical for a successful LD vaccination program.

Indexed as

Attitude of Health PersonnelHealth PersonnelLyme DiseaseLyme Disease VaccinesPatient Acceptance of Health CareVaccinationVaccination HesitancyAdultCross-Sectional StudiesFemaleHumansMaleMiddle AgedSurveys and QuestionnairesUnited StatesLyme Disease VaccinesBorrelia burgdorferiHealthcare providersLyme diseaseVaccination recommendationVaccine

Identifiers

PMID40680377
PMCPMC12673674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.